My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nevro Corp. Common Stock (NY:NVRO)

5.840 UNCHANGED
Last Price Updated: 7:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nevro Corp. Common Stock

< Previous 1 2 3 4 5 Next >
Why Nevro Shares Are Trading Lower By Around 19%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Aditxt, Inc. (NASDAQ: ADTX) shares gained 68.6% to $1.45. Aditxt signed asset purchase agreement to acquire 50% ownership of Global Response Aid with rights to manufacture and market... 
Via Benzinga
Why Nevro Stock Is Tanking Today
The moody market is punishing this medical device stock yet again today. 
Via The Motley Fool
Dow Tumbles 150 Points; Tesla Shares Drop After Q1 Results
U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.50% to 33,727.89 while the NASDAQ fell 0.49%... 
Via Benzinga
5 Analysts Have This to Say About Nevro
 
Via Benzinga
Earnings Scheduled For February 16, 2023
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Earnings Preview For Nevro
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023
 
Via Benzinga
Analyst Looks For Improvement Signs For Nevro's Core Market In 2023 After Mixed Q4 Earnings
 
Via Benzinga
Where Nevro Stands With Analysts
 
Via Benzinga
Where Nevro Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Nevro (NYSE:NVRO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
Recap: Nevro Q2 Earnings
Nevro (NYSE:NVRO) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Nevro beat estimated earnings by 13.41%,... 
Via Benzinga
Nevro's Return On Capital Employed Overview
Benzinga Pro data, Nevro (NYSE:NVRO) reported Q1 sales of $87.84 million. Earnings fell to a loss of $34.33 million, resulting in a 13.91% decrease from last quarter. 
Via Benzinga
Where Nevro Stands With Analysts
Nevro (NYSE:NVRO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Expert Ratings For Nevro
Within the last quarter, Nevro (NYSE:NVRO) has observed the following analyst ratings: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023
 
Via Benzinga
Where Nevro Stands With Analysts
 
Via Benzinga
Nevro Secures FDA Nod HFX iQ Spinal Cord Stimulation System For to Personalize Pain Treatment
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023
 
Via Benzinga
What 4 Analyst Ratings Have To Say About Nevro
Analysts have provided the following ratings for Nevro (NYSE:NVRO) within the last quarter: 
Via Benzinga
Nevro Wins Multiple Coverage Options For Spinal Cord Stimulation In Diabetic Neuropathy
 
Via Benzinga
Nevro's Return On Capital Employed Overview
  
Via Benzinga
Recap: Nevro Q4 Earnings
Nevro (NYSE:NVRO) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Nevro... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2022
 
Via Benzinga
Expert Ratings for Nevro
Over the past 3 months, 6 analysts have published their opinion on Nevro (NYSE:NVRO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
Recap: Nevro Q1 Earnings
Nevro (NYSE:NVRO) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Nevro beat estimated earnings by 10.91%,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022
 
Via Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
Upgrades 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 73 stocks hit new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.